Randomized Trial of Paclitaxel- Versus Sirolimus-Eluting Stents for Treatment of Coronary Restenosis in Sirolimus-Eluting Stents. The ISAR-DESIRE 2 (Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for In-Stent Restenosis 2) Study

Journal of the American College of Cardiology

Volumn 55, Issue 24, 2010, Pages 2710-2716

  Mehilli, Julinda ^a   Byrne, Robert A ^a   Tiroch, Klaus ^a   Pinieck, Susanne ^a   Schulz, Stefanie ^a   Kufner, Sebastian ^a   Massberg, Steffen ^a   Laugwitz, Karl Ludwig ^b   Schömig, Albert ^b   Kastrati, Adnan ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

drug eluting stent; in stent restenosis; randomized trial; resistance; sirolimus

Indexed keywords

'TAXUS'; ACETYLSALICYLIC ACID; CLOPIDOGREL; CYPHER; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG; PACLITAXEL; RAPAMYCIN; UNCLASSIFIED DRUG;

ADULT; AGED; ANGIOCARDIOGRAPHY; ANTICOAGULANT THERAPY; ARTICLE; CARDIAC PATIENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; DRUG EFFICACY; DRUG ELUTING STENT; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GERMANY; HEART DEATH; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; IN-STENT RESTENOSIS; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PATIENT SAFETY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; STENT THROMBOSIS; THERAPY EFFECT;

AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CORONARY ANGIOGRAPHY; CORONARY RESTENOSIS; DRUG-ELUTING STENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MYOCARDIAL REVASCULARIZATION; PACLITAXEL; RECURRENCE; RETROSPECTIVE STUDIES; SIROLIMUS; TREATMENT OUTCOME;

EID: 77953098629     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2010.02.009     Document Type: Article

References (26)

1. Byrne R.A., Sarafoff N., Kastrati A., and Schomig A. Drug-eluting stents in percutaneous coronary intervention: a benefit-risk assessment. Drug Saf 32 (2009) 749-770
2. Lloyd-Jones D., Adams R., Carnethon M., et al. Heart disease and stroke statistics-2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 119 (2009) 480-486
3. Torguson R., Sabate M., Deible R., et al. Intravascular brachytherapy versus drug-eluting stents for the treatment of patients with drug-eluting stent restenosis. Am J Cardiol 98 (2006) 1340-1344
4. Cosgrave J., Melzi G., Corbett S., et al. Repeated drug-eluting stent implantation for drug-eluting stent restenosis: the same or a different stent. Am Heart J 153 (2007) 354-359
5. Byrne R., Iijima R., Mehilli J., et al. Treatment of paclitaxel-eluting stent restenosis with sirolimus-eluting stent implantation: angiographic and clinical outcomes. Rev Esp Cardiol 61 (2008) 1134-1139
6. Kastrati A., Mehilli J., von Beckerath N., et al. Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial. JAMA 293 (2005) 165-171
7. Holmes Jr. D.R., Teirstein P., Satler L., et al. Sirolimus-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the SISR randomized trial. JAMA 295 (2006) 1264-1273
8. Stone G.W., Ellis S.G., O'Shaughnessy C.D., et al. Paclitaxel-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the TAXUS V ISR randomized trial. JAMA 295 (2006) 1253-1263
9. Alfonso F., Perez-Vizcayno M.J., Hernandez R., et al. A randomized comparison of sirolimus-eluting stent with balloon angioplasty in patients with in-stent restenosis: results of the Restenosis Intrastent: Balloon Angioplasty Versus Elective Sirolimus-Eluting Stenting (RIBS-II) trial. J Am Coll Cardiol 47 (2006) 2152-2160
10. Mehilli J., Kastrati A., Wessely R., et al. Randomized trial of a nonpolymer-based rapamycin-eluting stent versus a polymer-based paclitaxel-eluting stent for the reduction of late lumen loss. Circulation 113 (2006) 273-279
11. Mehran R., Dangas G., Abizaid A.S., et al. Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome. Circulation 100 (1999) 1872-1878
12. Byrne R.A., Kastrati A., Kufner S., et al. Randomized, non-inferiority trial of three limus agent-eluting stents with different polymer coatings: the Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST-4) trial. Eur Heart J 30 (2009) 2441-2449
13. Cutlip D.E., Windecker S., Mehran R., et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 115 (2007) 2344-2351
14. Steinberg D.H., Gaglia Jr. M.A., Pinto Slottow T.L., et al. Outcome differences with the use of drug-eluting stents for the treatment of in-stent restenosis of bare-metal stents versus drug-eluting stents. Am J Cardiol 103 (2009) 491-495
15. Lee S.S., Price M.J., Wong G.B., et al. Early- and medium-term outcomes after paclitaxel-eluting stent implantation for sirolimus-eluting stent failure. Am J Cardiol 98 (2006) 1345-1348
16. Garg S., Smith K., Torguson R., et al. Treatment of drug-eluting stent restenosis with the same versus different drug-eluting stent. Catheter Cardiovasc Interv 70 (2007) 9-14
17. Mishkel G.J., Moore A.L., Markwell S., Shelton M.C., and Shelton M.E. Long-term outcomes after management of restenosis or thrombosis of drug-eluting stents. J Am Coll Cardiol 49 (2007) 181-184
18. Nakazawa G., Vorpahl M., Finn A.V., Narula J., and Virmani R. One step forward and two steps back with drug-eluting-stents: from preventing restenosis to causing late thrombosis and nouveau atherosclerosis. J Am Coll Cardiol Img 2 (2009) 625-628
19. Dibra A., Kastrati A., Mehilli J., et al. Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients. N Engl J Med 353 (2005) 663-670
20. Mehilli J., Dibra A., Kastrati A., Pache J., Dirschinger J., and Schömig A. Randomized trial of paclitaxel- and sirolimus-eluting stents in small coronary vessels. Eur Heart J 27 (2006) 260-266
21. Windecker S., Remondino A., Eberli F.R., et al. Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. N Engl J Med 353 (2005) 653-662
22. Kurmasheva R.T., Huang S., and Houghton P.J. Predicted mechanisms of resistance to mTOR inhibitors. Br J Cancer 95 (2006) 955-960
23. Scheller B., Hehrlein C., Bocksch W., et al. Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. N Engl J Med 355 (2006) 2113-2124
24. Kuntz R.E., Keaney K.M., Senerchia C., and Baim D.S. A predictive method for estimating the late angiographic results of coronary intervention despite incomplete ascertainment. Circulation 87 (1993) 815-830
25. Byrne R.A., Iijima R., Mehilli J., et al. Durability of antirestenotic efficacy in drug-eluting stents with and without permanent polymer. J Am Coll Cardiol Intv 2 (2009) 291-299
26. Pinto D.S., Stone G.W., Ellis S.G., et al. Impact of routine angiographic follow-up on the clinical benefits of paclitaxel-eluting stents: results from the TAXUS-IV trial. J Am Coll Cardiol 48 (2006) 32-36